Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31026506 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL6693749 | 0.95 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL29386254 | 0.93 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL31333138 | 0.93 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL29984901 | 0.89 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL550215 | 0.89 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL2806223 | 0.84 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL30947333 | 0.83 | CYP3A4 (0.69) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL12560714 | 0.81 | KDM4E (0.61) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E | |
| SCHEMBL3978730 | 0.80 | CYP3A4 (0.55) | CYP3A4CYP2C9CYP2C19CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108191736-B | 2, 3-disubstituted indole derivatives and preparation method thereof | 盐城工学院 | 2020-05-12 | — | — | CN | disclosed |
| WO-2017168007-A1 | ANALOGS OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION | OMEICOS THERAPEUTICS GMBH (DE) | 2017-10-05 | — | — | WO | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-12-08 | — | — | US | disclosed |
| EP-3089977-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015102426-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-07-09 | — | — | WO | disclosed |
| EP-0498723-B1 | Nitrogen containing bicycle compounds, method for their preparation, their use as pharmaceutical and compositions containing them | AVENTIS PHARMA SA (FR) | 2001-09-19 | — | — | EP | disclosed |
| EP-0498721-B1 | N-substituted quinoline derivatives, process for their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL INC (FR) | 1999-12-22 | — | — | EP | disclosed |
| US-6004979-A | ANGIOTENSIN II INHIBITORS; 4-((CARBOXY)ARYLOXY)-QUINOLINE DERIVATIVES | HOECHST MARION ROUSSEL (FR) | 1999-12-21 | — | — | US | disclosed |
| US-5985894-A | USEFUL IN THE TREATMENT OF CARDIOVASCULAR ILLNESSES | HOECHST MARION ROUSSEL (FR) | 1999-11-16 | — | — | US | disclosed |
| US-5817674-A | ANTIOTENSIN II RECEPTOR ANTAGONISTS | ROUSSEL UCLAF (FR) | 1998-10-06 | — | — | US | disclosed |
| EP-0498722-B1 | Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1997-07-30 | — | — | EP | disclosed |
| US-5478938-A | Antagonists for angiotensin II receptors; hypotensive, cardiotonic agents; cognitive activators | ROUSSEL UCLAF (FR) | 1995-12-26 | — | — | US | disclosed |
| US-5324839-A | Hypotensive agents, gastrointestinal and urogenital disorders | ROUSSEL-UCLAF (FR) | 1994-06-28 | — | — | US | disclosed |
| EP-0498723-A1 | Nitrogen containing bicycle compounds, method for their preparation, their use as pharmaceutical and compositions containing them | ROUSSEL UCLAF (FR) | 1992-08-12 | — | — | EP | disclosed |
| EP-0498722-A1 | Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-08-12 | — | — | EP | disclosed |
| EP-0498721-A1 | N-substituted quinoline derivatives, process for their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355475-A1 | NOVEL INDOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC2, HDAC1, HDAC3 | CYP3A4 1064/4885CYP2C9 1687/4885CYP2C19 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.